Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1992 Nov;90(5):1889–1900. doi: 10.1172/JCI116066

Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.

K Aalto-Setälä 1, E A Fisher 1, X Chen 1, T Chajek-Shaul 1, T Hayek 1, R Zechner 1, A Walsh 1, R Ramakrishnan 1, H N Ginsberg 1, J L Breslow 1
PMCID: PMC443250  PMID: 1430212

Abstract

Hypertriglyceridemia is common in the general population, but its mechanism is largely unknown. In previous work human apo CIII transgenic (HuCIIITg) mice were found to have elevated triglyceride levels. In this report, the mechanism for the hypertriglyceridemia was studied. Two different HuCIIITg mouse lines were used: a low expressor line with serum triglycerides of approximately 280 mg/dl, and a high expressor line with serum triglycerides of approximately 1,000 mg/dl. Elevated triglycerides were mainly in VLDL. VLDL particles were 1.5 times more triglyceride-rich in high expressor mice than in controls. The total amount of apo CIII (human and mouse) per VLDL particle was 2 and 2.5 times the normal amount in low and high expressors, respectively. Mouse apo E was decreased by 35 and 77% in low and high expressor mice, respectively. Under electron microscopy, VLDL particles from low and high expressor mice were found to have a larger mean diameter, 55.2 +/- 16.6 and 58.2 +/- 17.8 nm, respectively, compared with 51.0 +/- 13.4 nm from control mice. In in vivo studies, radiolabeled VLDL fractional catabolic rate (FCR) was reduced in low and high expressor mice to 2.58 and 0.77 pools/h, respectively, compared with 7.67 pools/h in controls, with no significant differences in the VLDL production rates. In an attempt to explain the reduced VLDL FCR in transgenic mice, tissue lipoprotein lipase (LPL) activity was determined in control and high expressor mice and no differences were observed. Also, VLDLs obtained from control and high expressor mice were found to be equally good substrates for purified LPL. Thus excess apo CIII in HuCIIITg mice does not cause reduced VLDL FCR by suppressing the amount of extractable LPL in tissues or making HuCIIITg VLDL a bad substrate for LPL. Tissue uptake of VLDL was studied in hepatoma cell cultures, and VLDL from transgenic mice was found to be taken up much more slowly than control VLDL (P < 0.0001), indicating that HuCIIITg VLDL is not well recognized by lipoprotein receptors. Additional in vivo studies with Triton-treated mice showed increased VLDL triglyceride, but not apo B, production in the HuCIIITg mice compared with controls. Tissue culture studies with primary hepatocytes showed a modest increase in triglyceride, but not apo B or total protein, secretion in high expressor mice compared with controls. In summary, hypertriglyceridemia in HuCIIITg mice appears to result primarily from decreased tissue uptake of triglyceride-rich particles from the circulation, which is most likely due to increased apo CIII and decreased apo E on VLDL particles. the HuCIIITg mouse appears to be a suitable animal model of primary familial hypertriglyceridemia, and these studies suggest a possible mechanism for this common lipoprotein disorder.

Full text

PDF
1889

Images in this article

1893Image
on p.1893
1893Image
on p.1893
1894Image
on p.1894
1894Image
on p.1894

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arad Y., Ramakrishnan R., Ginsberg H. N. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J Lipid Res. 1990 Apr;31(4):567–582. [PubMed] [Google Scholar]
  2. Barton R. N. The interconversion and disposal of ketone bodies in untreated and injured post-absorptive rats. Biochem J. 1973 Nov;136(3):531–543. doi: 10.1042/bj1360531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Belfrage P., Vaughan M. Simple liquid-liquid partition system for isolation of labeled oleic acid from mixtures with glycerides. J Lipid Res. 1969 May;10(3):341–344. [PubMed] [Google Scholar]
  4. Bradley W. A., Hwang S. L., Karlin J. B., Lin A. H., Prasad S. C., Gotto A. M., Jr, Gianturco S. H. Low-density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low-density lipoproteins. J Biol Chem. 1984 Dec 10;259(23):14728–14735. [PubMed] [Google Scholar]
  5. Brinton E. A., Eisenberg S., Breslow J. L. Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women. J Clin Invest. 1989 Jul;84(1):262–269. doi: 10.1172/JCI114149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brown W. V., Baginsky M. L. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun. 1972 Jan 31;46(2):375–382. doi: 10.1016/s0006-291x(72)80149-9. [DOI] [PubMed] [Google Scholar]
  7. Chait A., Albers J. J., Brunzell J. D. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia. Eur J Clin Invest. 1980 Feb;10(1):17–22. doi: 10.1111/j.1365-2362.1980.tb00004.x. [DOI] [PubMed] [Google Scholar]
  8. DOLE V. P. A relation between non-esterified fatty acids in plasma and the metabolism of glucose. J Clin Invest. 1956 Feb;35(2):150–154. doi: 10.1172/JCI103259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Egusa G., Beltz W. F., Grundy S. M., Howard B. V. Influence of obesity on the metabolism of apolipoprotein B in humans. J Clin Invest. 1985 Aug;76(2):596–603. doi: 10.1172/JCI112011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ellsworth J. L., Erickson S. K., Cooper A. D. Very low and low density lipoprotein synthesis and secretion by the human hepatoma cell line Hep-G2: effects of free fatty acid. J Lipid Res. 1986 Aug;27(8):858–874. [PubMed] [Google Scholar]
  11. FOLCH J., LEES M., SLOANE STANLEY G. H. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957 May;226(1):497–509. [PubMed] [Google Scholar]
  12. Fojo S. S., de Gennes J. L., Beisiegel U., Baggio G., Stalenhoef A. F., Brunzell J. D., Brewer H. B., Jr Molecular genetics of apoC-II and lipoprotein lipase deficiency. Adv Exp Med Biol. 1991;285:329–333. doi: 10.1007/978-1-4684-5904-3_40. [DOI] [PubMed] [Google Scholar]
  13. Forte T. M., Nordhausen R. W. Electron microscopy of negatively stained lipoproteins. Methods Enzymol. 1986;128:442–457. doi: 10.1016/0076-6879(86)28086-6. [DOI] [PubMed] [Google Scholar]
  14. Gianturco S. H., Gotto A. M., Jr, Hwang S. L., Karlin J. B., Lin A. H., Prasad S. C., Bradley W. A. Apolipoprotein E mediates uptake of Sf 100-400 hypertriglyceridemic very low density lipoproteins by the low density lipoprotein receptor pathway in normal human fibroblasts. J Biol Chem. 1983 Apr 10;258(7):4526–4533. [PubMed] [Google Scholar]
  15. Ginsberg H. N., Le N. A., Gibson J. C. Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss. J Clin Invest. 1985 Feb;75(2):614–623. doi: 10.1172/JCI111739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Goldstein J. L., Brown M. S. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem. 1974 Aug 25;249(16):5153–5162. [PubMed] [Google Scholar]
  17. HAVEL R. J., EDER H. A., BRAGDON J. H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955 Sep;34(9):1345–1353. doi: 10.1172/JCI103182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ito Y., Azrolan N., O'Connell A., Walsh A., Breslow J. L. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science. 1990 Aug 17;249(4970):790–793. doi: 10.1126/science.2167514. [DOI] [PubMed] [Google Scholar]
  19. Jackson R. L., Tajima S., Yamamura T., Yokoyama S., Yamamoto A. Comparison of apolipoprotein C-II-deficient triacylglycerol-rich lipoproteins and trioleoylglycerol/phosphatidylcholine-stabilized particles as substrates for lipoprotein lipase. Biochim Biophys Acta. 1986 Feb 12;875(2):211–219. doi: 10.1016/0005-2760(86)90170-0. [DOI] [PubMed] [Google Scholar]
  20. Janero D. R., Siuta-Mangano P., Miller K. W., Lane M. D. Synthesis, processing, and secretion of hepatic very low density lipoprotein. J Cell Biochem. 1984;24(2):131–152. doi: 10.1002/jcb.240240205. [DOI] [PubMed] [Google Scholar]
  21. Janus E. D., Nicoll A. M., Turner P. R., Magill P., Lewis B. Kinetic bases of the primary hyperlipidaemias: studies of apolipoprotein B turnover in genetically defined subjects. Eur J Clin Invest. 1980 Apr;10(2 Pt 1):161–172. doi: 10.1111/j.1365-2362.1980.tb02076.x. [DOI] [PubMed] [Google Scholar]
  22. Janus E. D., Nicoll A., Wootton R., Turner P. R., Magill P. J., Lewis B. Quantitative studies of very low density lipoprotein: conversion to low density lipoprotein in normal controls and primary hyperlipidaemic states and the role of direct secretion of low density lipoprotein in heterozygous familial hypercholesterolaemia. Eur J Clin Invest. 1980 Apr;10(2 Pt 1):149–159. doi: 10.1111/j.1365-2362.1980.tb02075.x. [DOI] [PubMed] [Google Scholar]
  23. Johnson W. J., Bamberger M. J., Latta R. A., Rapp P. E., Phillips M. C., Rothblat G. H. The bidirectional flux of cholesterol between cells and lipoproteins. Effects of phospholipid depletion of high density lipoprotein. J Biol Chem. 1986 May 5;261(13):5766–5776. [PubMed] [Google Scholar]
  24. Kesäniemi Y. A., Beltz W. F., Grundy S. M. Comparisons of metabolism of apolipoprotein B in normal subjects, obese patients, and patients with coronary heart disease. J Clin Invest. 1985 Aug;76(2):586–595. doi: 10.1172/JCI112010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kissebah A. H., Alfarsi S., Adams P. W. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. Metabolism. 1981 Sep;30(9):856–868. doi: 10.1016/0026-0495(81)90064-0. [DOI] [PubMed] [Google Scholar]
  26. Kissebah A. H., Alfarsi S., Evans D. J. Low density lipoprotein metabolism in familial combined hyperlipidemia. Mechanism of the multiple lipoprotein phenotypic expression. Arteriosclerosis. 1984 Nov-Dec;4(6):614–624. doi: 10.1161/01.atv.4.6.614. [DOI] [PubMed] [Google Scholar]
  27. Kohout M., Kohoutova B., Heimberg M. The regulation of hepatic triglyceride metabolism by free fatty acids. J Biol Chem. 1971 Aug 25;246(16):5067–5074. [PubMed] [Google Scholar]
  28. Kowal R. C., Herz J., Weisgraber K. H., Mahley R. W., Brown M. S., Goldstein J. L. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem. 1990 Jun 25;265(18):10771–10779. [PubMed] [Google Scholar]
  29. Krauss R. M., Herbert P. N., Levy R. I., Fredrickson D. S. Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins. Circ Res. 1973 Oct;33(4):403–411. doi: 10.1161/01.res.33.4.403. [DOI] [PubMed] [Google Scholar]
  30. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  31. Le N. A., Gibson J. C., Ginsberg H. N. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. J Lipid Res. 1988 May;29(5):669–677. [PubMed] [Google Scholar]
  32. Miller N. E., Rao S. N., Alaupovic P., Noble N., Slack J., Brunzell J. D., Lewis B. Familial apolipoprotein CII deficiency: plasma lipoproteins and apolipoproteins in heterozygous and homozygous subjects and the effects of plasma infusion. Eur J Clin Invest. 1981 Feb;11(1):69–76. doi: 10.1111/j.1365-2362.1981.tb01768.x. [DOI] [PubMed] [Google Scholar]
  33. Nilsson-Ehle P., Schotz M. C. A stable, radioactive substrate emulsion for assay of lipoprotein lipase. J Lipid Res. 1976 Sep;17(5):536–541. [PubMed] [Google Scholar]
  34. Ordovas J. M., Civeira F., Genest J., Jr, Craig S., Robbins A. H., Meade T., Pocovi M., Frossard P. M., Masharani U., Wilson P. W. Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis. 1991 Mar;87(1):75–86. doi: 10.1016/0021-9150(91)90234-t. [DOI] [PubMed] [Google Scholar]
  35. Sane T., Nikkilä E. A. Very low density lipoprotein triglyceride metabolism in relatives of hypertriglyceridemic probands. Evidence for genetic control of triglyceride removal. Arteriosclerosis. 1988 May-Jun;8(3):217–226. doi: 10.1161/01.atv.8.3.217. [DOI] [PubMed] [Google Scholar]
  36. Schonfeld G., Bell E., Alpers D. H. Intestinal apoproteins during fat absorption. J Clin Invest. 1978 Jun;61(6):1539–1550. doi: 10.1172/JCI109074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Schonfeld G., George P. K., Miller J., Reilly P., Witztum J. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism. 1979 Oct;28(10):1001–1010. doi: 10.1016/0026-0495(79)90004-0. [DOI] [PubMed] [Google Scholar]
  38. Schonfeld G., Pfleger B. Utilization of exogenous free fatty acids for the production of very low density lipoprotein triglyceride by livers of carbohydrate-fed rats. J Lipid Res. 1971 Sep;12(5):614–621. [PubMed] [Google Scholar]
  39. Sehayek E., Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 1991 Sep 25;266(27):18259–18267. [PubMed] [Google Scholar]
  40. Sehayek E., Lewin-Velvert U., Chajek-Shaul T., Eisenberg S. Lipolysis exposes unreactive endogenous apolipoprotein E-3 in human and rat plasma very low density lipoprotein. J Clin Invest. 1991 Aug;88(2):553–560. doi: 10.1172/JCI115339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Shelburne F., Hanks J., Meyers W., Quarfordt S. Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat. J Clin Invest. 1980 Mar;65(3):652–658. doi: 10.1172/JCI109710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Shoulders C. C., Harry P. J., Lagrost L., White S. E., Shah N. F., North J. D., Gilligan M., Gambert P., Ball M. J. Variation at the apo AI/CIII/AIV gene complex is associated with elevated plasma levels of apo CIII. Atherosclerosis. 1991 Apr;87(2-3):239–247. doi: 10.1016/0021-9150(91)90026-y. [DOI] [PubMed] [Google Scholar]
  43. Simonet W. S., Bucay N., Pitas R. E., Lauer S. J., Taylor J. M. Multiple tissue-specific elements control the apolipoprotein E/C-I gene locus in transgenic mice. J Biol Chem. 1991 May 15;266(14):8651–8654. [PubMed] [Google Scholar]
  44. Sparks C. E., Sparks J. D., Bolognino M., Salhanick A., Strumph P. S., Amatruda J. M. Insulin effects on apolipoprotein B lipoprotein synthesis and secretion by primary cultures of rat hepatocytes. Metabolism. 1986 Dec;35(12):1128–1136. doi: 10.1016/0026-0495(86)90026-0. [DOI] [PubMed] [Google Scholar]
  45. Weber K., Osborn M. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem. 1969 Aug 25;244(16):4406–4412. [PubMed] [Google Scholar]
  46. Weisgraber K. H., Mahley R. W., Kowal R. C., Herz J., Goldstein J. L., Brown M. S. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. J Biol Chem. 1990 Dec 25;265(36):22453–22459. [PubMed] [Google Scholar]
  47. Windler E. E., Kovanen P. T., Chao Y. S., Brown M. S., Havel R. J., Goldstein J. L. The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J Biol Chem. 1980 Nov 10;255(21):10464–10471. [PubMed] [Google Scholar]
  48. Windler E., Chao Y., Havel R. J. Determinants of hepatic uptake of triglyceride-rich lipoproteins and their remnants in the rat. J Biol Chem. 1980 Jun 10;255(11):5475–5480. [PubMed] [Google Scholar]
  49. Windler E., Chao Y., Havel R. J. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins. J Biol Chem. 1980 Sep 10;255(17):8303–8307. [PubMed] [Google Scholar]
  50. Windler E., Havel R. J. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res. 1985 May;26(5):556–565. [PubMed] [Google Scholar]
  51. Zechner R. Rapid and simple isolation procedure for lipoprotein lipase from human milk. Biochim Biophys Acta. 1990 May 1;1044(1):20–25. doi: 10.1016/0005-2760(90)90213-h. [DOI] [PubMed] [Google Scholar]
  52. van't Hooft F., Havel R. J. Metabolism of chromatographically separated rat serum lipoproteins specifically labeled with 125I-apolipoprotein E. J Biol Chem. 1981 Apr 25;256(8):3963–3968. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES